NDT Advance Access originally published online on June 23, 2009
Nephrology Dialysis Transplantation 2009 24(9):2620-2622; doi:10.1093/ndt/gfp313
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Preserving residual renal function in peritoneal dialysis: volume or biocompatibility?
Institute of Science and Technology in Medicine, Keele University and Department of Nephrology, University Hospital of North Staffordshire, Stoke-on-Trent, Staffordshire, UK
Correspondence and offprint requests to: Simon Davies; E-mail: simondavies1@compuserve.com
| The first 150 words of the full text of this article appear below. |
Leaving life-style issues aside, preservation of residual renal function (RRF) is seen as one of the main clinical benefits of peritoneal dialysis (PD) as a treatment modality choice. The majority of studies have indicated that RRF is relatively well preserved in comparison to haemodialysis (HD) [1,2] and two major hypotheses have emerged to explain this difference: (i) relative stability of volume status—perhaps even a tendency to develop hypervolaemia in PD compared to HD, where fluctuations in volume are common, especially when attempts are made to control blood pressure principally by manipulation of volume and (ii) the biocompatibility of the dialysis fluids. In the case of HD, there is evidence that ultrapure dialysate preserves RRF [3], whereas in PD it has been suggested that the newer biocompatible fluids, which contain reduced levels of glucose degradation products (GDPs), lead to reduced circulating levels of these potentially nephrotoxic substances